Floatz logo

Toripalimab

Mismatch Repair-deficient (dMMR)

Sun Yat-sen Universitymonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Mismatch Repair-deficient (dMMR) cohort.

Asset / SponsorPhaseRating
Dfn-15
Sun Yat-sen University
Phase 2CCC
Envafolimab
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2CCC
Carboplatin
Sun Yat-sen University
Phase 1/2CCC

Same molecule, other indications

Toripalimab is also rated in:

renal cell carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
ToripalimabDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →